<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608062</url>
  </required_header>
  <id_info>
    <org_study_id>06-0537</org_study_id>
    <secondary_id>R01AG027678</secondary_id>
    <nct_id>NCT00608062</nct_id>
  </id_info>
  <brief_title>Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women</brief_title>
  <acronym>SHAPE</acronym>
  <official_title>Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out why women's arteries stiffen as they go through&#xD;
      menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with&#xD;
      the loss of estrogen because of &quot;oxidative stress,&quot; the production of molecules that can&#xD;
      damage cells and tissues in the body, and because the arteries lose their ability to expand,&#xD;
      or dilate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As women get older and go through menopause, estradiol levels decrease. Also with aging, the&#xD;
      arteries that are located around the heart get stiffer. Over time this increase in arterial&#xD;
      stiffness can lead to a number of health problems such as high blood pressure and heart&#xD;
      disease. In this study we want to find out if a short-term drop in estrogen levels in&#xD;
      premenopausal and perimenopausal women can cause arteries to become stiffer, and why this&#xD;
      happens. Additionally, in postmenopausal women, we want to find out if a short-term increase&#xD;
      in estrogen levels causes their arteries to become more flexible (less stiff).&#xD;
&#xD;
      Arterial health (i.e., stiffness) will be examined in premenopausal, perimenopausal and&#xD;
      postmenopausal women before and after they are given a drug called Ganirelix™ (for 7 days),&#xD;
      which will markedly lower their reproductive hormones. After the first 4 days of taking&#xD;
      Ganirelix™, the women will be randomly placed into 1 of 2 treatment groups to take either&#xD;
      estrogen (0.075 mg/d skin patch) replacement or placebo for the rest of the Ganirelix&#xD;
      treatment. This is to increase estrogen levels back to the normal level. After having the&#xD;
      patch on for 4 days, arterial health will be examined again.&#xD;
&#xD;
      Pre-specified Outcome Measures were divided into unit-of-measurement specific Outcome Measure&#xD;
      tables for the purposes of results reporting to ClinicalTrials.gov&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 25, 2012</completion_date>
  <primary_completion_date type="Actual">October 25, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Stiffness (Carotid Artery Compliance) During Saline</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
    <description>Carotid artery compliance measured by carotid artery ultrasound and brachial artery blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>Baseline, day 4 of GnRHant and Day 7 of GnRHant and estradiol or placebo treatment</time_frame>
    <description>Brachial artery flow-mediated dilation (FMD) assessed by ultrasound. This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Primary&quot; to be consistent with the protocol.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Supine Brachial Blood Pressures</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Estradiol</measure>
    <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
    <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum estradiol for clinical characteristics and to detect changes in estradiol levels with the interventions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progesterone</measure>
    <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
    <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum progesterone was measured for clinical characteristics and to determine changes in sex hormones.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Antioxidant Status (TAS)</measure>
    <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
    <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. TAS is an antioxidant and is a biomarker of oxidative stress.</description>
  </other_outcome>
  <other_outcome>
    <measure>Endothelin-1 (ET-1)</measure>
    <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
    <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Norepinephrine</measure>
    <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
    <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Arterial Stiffening</condition>
  <condition>Aging</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Pre1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Premenopausal - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perimenopausal (early) - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perimenopausal (early) - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perimenopausal (late) - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perimenopausal (late) - GnRHant plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal - GnRHant plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Postmenopausal - GnRHant plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRHant - Ganirelix acetate</intervention_name>
    <description>1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7</description>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_label>Post1</arm_group_label>
    <arm_group_label>Post2</arm_group_label>
    <arm_group_label>Pre1</arm_group_label>
    <arm_group_label>Pre2</arm_group_label>
    <other_name>Ganirelix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol patch</intervention_name>
    <description>0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
    <arm_group_label>Peri1</arm_group_label>
    <arm_group_label>Peri3</arm_group_label>
    <arm_group_label>Post1</arm_group_label>
    <arm_group_label>Pre1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal placebo patch</intervention_name>
    <description>Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
    <arm_group_label>Peri2</arm_group_label>
    <arm_group_label>Peri4</arm_group_label>
    <arm_group_label>Post2</arm_group_label>
    <arm_group_label>Pre2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women of all races and ethnic backgrounds in one of the following groups:&#xD;
&#xD;
               -  Premenopausal: 18-49 years, regular menstrual cycles with no change in observed&#xD;
                  cycle length (21-35 days)&#xD;
&#xD;
               -  Perimenopausal: 40-55 years, categorized as either early (at least 2 cycles with&#xD;
                  cycle length changes of at least 7 days) or late (more than 3 months of&#xD;
                  amenorrhea) transition&#xD;
&#xD;
               -  Postmenopausal: 45-70 years, more than 12 months of amenorrhea as defined by the&#xD;
                  menopausal staging system (STRAW); additionally, postmenopausal women will be&#xD;
                  categorized into early and late stages as defined by the STRAW definition,&#xD;
                  specifically, women who are less than 5 years postmenopause will be considered&#xD;
                  early, and women more than 6 years will be categorized as late&#xD;
&#xD;
          -  All postmenopausal women will have undergone natural menopause&#xD;
&#xD;
          -  No oral contraceptive or Hormone Replacement Therapy (HRT) use for at least 6 months&#xD;
&#xD;
          -  Resting blood pressure less than 140/90 mmHg&#xD;
&#xD;
          -  Plasma glucose concentrations less than 110 mg/dl under fasting conditions&#xD;
&#xD;
          -  Sedentary or recreationally active (less than 3 days of vigorous aerobic exercise)&#xD;
&#xD;
          -  No use of medications that might influence cardiovascular function&#xD;
&#xD;
          -  Nonsmokers&#xD;
&#xD;
          -  No use of vitamin supplements or willing to stop use for duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or active estrogen-dependent neoplasms, acute liver or gallbladder disease,&#xD;
             vaginal bleeding, venous thromboembolism, hypertriglyceridemia, and cardiovascular&#xD;
             disease&#xD;
&#xD;
          -  Known allergy to transdermal patch or GnRHant&#xD;
&#xD;
          -  Other contraindications to HRT and GnRHant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie L Moreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moreau KL, Donato AJ, Seals DR, DeSouza CA, Tanaka H. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res. 2003 Mar;57(3):861-8.</citation>
    <PMID>12618248</PMID>
  </reference>
  <reference>
    <citation>Moreau KL, Gavin KM, Plum AE, Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension. 2005 Jun;45(6):1107-12. Epub 2005 May 2.</citation>
    <PMID>15867135</PMID>
  </reference>
  <reference>
    <citation>Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, Buralli S, Taddei S, Salvetti A. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation. 2000 May 16;101(19):2258-63.</citation>
    <PMID>10811592</PMID>
  </reference>
  <reference>
    <citation>Ihionkhan CE, Chambliss KL, Gibson LL, Hahner LD, Mendelsohn ME, Shaul PW. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res. 2002 Nov 1;91(9):814-20.</citation>
    <PMID>12411396</PMID>
  </reference>
  <reference>
    <citation>Eskurza I, Monahan KD, Robinson JA, Seals DR. Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol. 2004 Apr 1;556(Pt 1):315-24. Epub 2004 Jan 30. Erratum in: J Physiol. 2004 May 1;556(Pt 3):1014.</citation>
    <PMID>14754992</PMID>
  </reference>
  <reference>
    <citation>Gavin KM, Jankowski C, Kohrt WM, Stauffer BL, Seals DR, Moreau KL. Hysterectomy is associated with large artery stiffening in estrogen-deficient postmenopausal women. Menopause. 2012 Sep;19(9):1000-7. doi: 10.1097/gme.0b013e31825040f9.</citation>
    <PMID>22692329</PMID>
  </reference>
  <reference>
    <citation>Moreau KL, Meditz A, Deane KD, Kohrt WM. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1211-8. doi: 10.1152/ajpheart.01065.2011. Epub 2012 Jan 13.</citation>
    <PMID>22245769</PMID>
  </reference>
  <results_reference>
    <citation>Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012 Dec;97(12):4692-700. doi: 10.1210/jc.2012-2244. Epub 2012 Sep 11.</citation>
    <PMID>22969140</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>December 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2020</results_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>women</keyword>
  <keyword>female</keyword>
  <keyword>estrogen deficiency</keyword>
  <keyword>sex hormones</keyword>
  <keyword>adiposity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>antioxidants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Denver metro area between March 2007 and March 2012. The first participant was enrolled on March 6, 2007 and the last participant was enrolled in March 2012.</recruitment_details>
      <pre_assignment_details>A total of 155 women consented to participate. During screening, 33 women did not qualify (12 premenopausal, 14 perimenopausal [11 early- and 3 late], and 7 postmenopausal). Twenty-three withdrew from participation before baseline testing and 7 women withdrew from participation after baseline testing but prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre1</title>
          <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="P2">
          <title>Pre2</title>
          <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="P3">
          <title>Peri1</title>
          <description>Perimenopausal (early and late combined) - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="P4">
          <title>Peri2</title>
          <description>Perimenopausal (early and late combined) - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="P5">
          <title>Post1</title>
          <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="P6">
          <title>Post2</title>
          <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">25 women completed baseline testing, 4 women withdrew prior to randomization</participants>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="19">43 women completed baseline testing, 3 women withdrew prior to randomization</participants>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For primary outcome brachial artery FMD, 91 completed the study. Four participants did not have usable FMD data due to poor ultrasound image quality or technical issues with image acquisition; baseline analysis and results for the remaining 87 women are presented.</population>
      <group_list>
        <group group_id="B1">
          <title>Pre1</title>
          <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B2">
          <title>Pre2</title>
          <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B3">
          <title>Peri1</title>
          <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B4">
          <title>Peri2</title>
          <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B5">
          <title>Post1</title>
          <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B6">
          <title>Post2</title>
          <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="13"/>
            <count group_id="B7" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="8"/>
                    <measurement group_id="B2" value="33" spread="7"/>
                    <measurement group_id="B3" value="49" spread="3"/>
                    <measurement group_id="B4" value="50" spread="4"/>
                    <measurement group_id="B5" value="56" spread="5"/>
                    <measurement group_id="B6" value="60" spread="6"/>
                    <measurement group_id="B7" value="47" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="15.6"/>
                    <measurement group_id="B2" value="64.2" spread="11.0"/>
                    <measurement group_id="B3" value="65.6" spread="8.1"/>
                    <measurement group_id="B4" value="68.7" spread="11.9"/>
                    <measurement group_id="B5" value="70.5" spread="14.7"/>
                    <measurement group_id="B6" value="69.7" spread="9.3"/>
                    <measurement group_id="B7" value="67.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="5.6"/>
                    <measurement group_id="B2" value="24.4" spread="5.3"/>
                    <measurement group_id="B3" value="24.1" spread="3.2"/>
                    <measurement group_id="B4" value="25.2" spread="3.9"/>
                    <measurement group_id="B5" value="26.7" spread="5.9"/>
                    <measurement group_id="B6" value="26.5" spread="2.7"/>
                    <measurement group_id="B7" value="25.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109" spread="8"/>
                    <measurement group_id="B2" value="110" spread="7"/>
                    <measurement group_id="B3" value="113" spread="14"/>
                    <measurement group_id="B4" value="115" spread="11"/>
                    <measurement group_id="B5" value="117" spread="14"/>
                    <measurement group_id="B6" value="120" spread="14"/>
                    <measurement group_id="B7" value="114" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="7"/>
                    <measurement group_id="B2" value="72" spread="5"/>
                    <measurement group_id="B3" value="71" spread="9"/>
                    <measurement group_id="B4" value="73" spread="6"/>
                    <measurement group_id="B5" value="73" spread="8"/>
                    <measurement group_id="B6" value="74" spread="10"/>
                    <measurement group_id="B7" value="72" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VO2peak</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="6.0"/>
                    <measurement group_id="B2" value="31.0" spread="5.5"/>
                    <measurement group_id="B3" value="27.7" spread="4.0"/>
                    <measurement group_id="B4" value="27.5" spread="5.8"/>
                    <measurement group_id="B5" value="24.8" spread="3.9"/>
                    <measurement group_id="B6" value="24.1" spread="2.9"/>
                    <measurement group_id="B7" value="28.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="0.3"/>
                    <measurement group_id="B2" value="4.6" spread="0.6"/>
                    <measurement group_id="B3" value="4.5" spread="0.3"/>
                    <measurement group_id="B4" value="4.7" spread="0.5"/>
                    <measurement group_id="B5" value="5.0" spread="0.7"/>
                    <measurement group_id="B6" value="4.6" spread="0.6"/>
                    <measurement group_id="B7" value="4.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin</title>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="21" upper_limit="66"/>
                    <measurement group_id="B2" value="42" lower_limit="30" upper_limit="85"/>
                    <measurement group_id="B3" value="28" lower_limit="21" upper_limit="66"/>
                    <measurement group_id="B4" value="28" lower_limit="21" upper_limit="66"/>
                    <measurement group_id="B5" value="28" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B6" value="31" lower_limit="23" upper_limit="82"/>
                    <measurement group_id="B7" value="35" lower_limit="28" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="0.7"/>
                    <measurement group_id="B2" value="4.0" spread="0.9"/>
                    <measurement group_id="B3" value="4.5" spread="0.9"/>
                    <measurement group_id="B4" value="4.2" spread="0.6"/>
                    <measurement group_id="B5" value="4.7" spread="0.9"/>
                    <measurement group_id="B6" value="4.7" spread="0.9"/>
                    <measurement group_id="B7" value="4.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density Lipoprotein</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="0.5"/>
                    <measurement group_id="B2" value="2.2" spread="0.7"/>
                    <measurement group_id="B3" value="2.7" spread="1.0"/>
                    <measurement group_id="B4" value="2.4" spread="0.5"/>
                    <measurement group_id="B5" value="2.9" spread="0.8"/>
                    <measurement group_id="B6" value="2.8" spread="0.9"/>
                    <measurement group_id="B7" value="2.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density Lipoprotein</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.1"/>
                    <measurement group_id="B2" value="1.3" spread="0.2"/>
                    <measurement group_id="B3" value="1.3" spread="0.2"/>
                    <measurement group_id="B4" value="1.3" spread="0.3"/>
                    <measurement group_id="B5" value="1.3" spread="0.3"/>
                    <measurement group_id="B6" value="1.3" spread="0.3"/>
                    <measurement group_id="B7" value="1.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arterial Stiffness (Carotid Artery Compliance) During Saline</title>
        <description>Carotid artery compliance measured by carotid artery ultrasound and brachial artery blood pressure</description>
        <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
        <population>Early and late perimenopausal were collapsed into 1 perimenopausal group</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal (early and late combined) - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal (early and late combined) - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Stiffness (Carotid Artery Compliance) During Saline</title>
          <description>Carotid artery compliance measured by carotid artery ultrasound and brachial artery blood pressure</description>
          <population>Early and late perimenopausal were collapsed into 1 perimenopausal group</population>
          <units>mm2/mm Hg×10-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.27"/>
                    <measurement group_id="O2" value="1.34" spread="0.18"/>
                    <measurement group_id="O3" value="0.90" spread="0.27"/>
                    <measurement group_id="O4" value="1.02" spread="0.33"/>
                    <measurement group_id="O5" value="0.89" spread="0.25"/>
                    <measurement group_id="O6" value="0.74" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.27"/>
                    <measurement group_id="O2" value="1.19" spread="0.34"/>
                    <measurement group_id="O3" value="0.89" spread="0.27"/>
                    <measurement group_id="O4" value="0.94" spread="0.29"/>
                    <measurement group_id="O5" value="0.85" spread="0.24"/>
                    <measurement group_id="O6" value="0.79" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant + Add-Back</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.26"/>
                    <measurement group_id="O2" value="1.14" spread="0.38"/>
                    <measurement group_id="O3" value="0.98" spread="0.27"/>
                    <measurement group_id="O4" value="0.94" spread="0.27"/>
                    <measurement group_id="O5" value="0.92" spread="0.27"/>
                    <measurement group_id="O6" value="0.80" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function</title>
        <description>Brachial artery flow-mediated dilation (FMD) assessed by ultrasound. This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Primary&quot; to be consistent with the protocol.</description>
        <time_frame>Baseline, day 4 of GnRHant and Day 7 of GnRHant and estradiol or placebo treatment</time_frame>
        <population>Numbers for some groups are reduced because of poor ultrasound image quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function</title>
          <description>Brachial artery flow-mediated dilation (FMD) assessed by ultrasound. This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Primary&quot; to be consistent with the protocol.</description>
          <population>Numbers for some groups are reduced because of poor ultrasound image quality.</population>
          <units>% Diameter Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="2.5"/>
                    <measurement group_id="O2" value="11.3" spread="2.5"/>
                    <measurement group_id="O3" value="7.7" spread="2.6"/>
                    <measurement group_id="O4" value="6.1" spread="2.7"/>
                    <measurement group_id="O5" value="5.4" spread="1.7"/>
                    <measurement group_id="O6" value="5.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 of GnRHant alone</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.3"/>
                    <measurement group_id="O2" value="8.9" spread="2.7"/>
                    <measurement group_id="O3" value="5.8" spread="2"/>
                    <measurement group_id="O4" value="6.6" spread="2"/>
                    <measurement group_id="O5" value="4.9" spread="1.5"/>
                    <measurement group_id="O6" value="4.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 of GnRHant plus treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="3.3"/>
                    <measurement group_id="O2" value="7.8" spread="3.0"/>
                    <measurement group_id="O3" value="9.6" spread="3.3"/>
                    <measurement group_id="O4" value="6.1" spread="2.7"/>
                    <measurement group_id="O5" value="8.4" spread="2.4"/>
                    <measurement group_id="O6" value="4.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Vitamin C Infusion Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="3.1"/>
                    <measurement group_id="O2" value="11.2" spread="4.8"/>
                    <measurement group_id="O3" value="9.3" spread="3.4"/>
                    <measurement group_id="O4" value="11.2" spread="3.6"/>
                    <measurement group_id="O5" value="7.8" spread="3.4"/>
                    <measurement group_id="O6" value="6.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Repeated measurements of FMD were modeled using a general linear mixed model with maximum likelihood estimation. An unstructured covariance structure allowing for heterogeneity in the parameter estimate for each level of menopause stage was chosen for the model based on using AIC to compare various covariance structures.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Supine Brachial Blood Pressures</title>
        <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Brachial Blood Pressures</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="10"/>
                    <measurement group_id="O2" value="108" spread="9"/>
                    <measurement group_id="O3" value="111" spread="13"/>
                    <measurement group_id="O4" value="109" spread="15"/>
                    <measurement group_id="O5" value="117" spread="10"/>
                    <measurement group_id="O6" value="123" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 of GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="7"/>
                    <measurement group_id="O2" value="111" spread="13"/>
                    <measurement group_id="O3" value="112" spread="12"/>
                    <measurement group_id="O4" value="108" spread="13"/>
                    <measurement group_id="O5" value="116" spread="9"/>
                    <measurement group_id="O6" value="115" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 of GnRHant plus treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="10"/>
                    <measurement group_id="O2" value="110" spread="14"/>
                    <measurement group_id="O3" value="108" spread="13"/>
                    <measurement group_id="O4" value="109" spread="16"/>
                    <measurement group_id="O5" value="112" spread="10"/>
                    <measurement group_id="O6" value="111" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Estradiol</title>
        <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum estradiol for clinical characteristics and to detect changes in estradiol levels with the interventions.</description>
        <time_frame>Baseline, day 4 of GnRHant and day 7 of GnRHant and estradiol or placebo treatment</time_frame>
        <population>Data are for subsample of women who completed FMD with useuable data</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol</title>
          <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum estradiol for clinical characteristics and to detect changes in estradiol levels with the interventions.</description>
          <population>Data are for subsample of women who completed FMD with useuable data</population>
          <units>pmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="117" upper_limit="332"/>
                    <measurement group_id="O2" value="270" lower_limit="128" upper_limit="484"/>
                    <measurement group_id="O3" value="360" lower_limit="46" upper_limit="508"/>
                    <measurement group_id="O4" value="147" lower_limit="62" upper_limit="316"/>
                    <measurement group_id="O5" value="39" lower_limit="37" upper_limit="49"/>
                    <measurement group_id="O6" value="37" lower_limit="37" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" lower_limit="87" upper_limit="183"/>
                    <measurement group_id="O2" value="127" lower_limit="96" upper_limit="243"/>
                    <measurement group_id="O3" value="92" lower_limit="37" upper_limit="468"/>
                    <measurement group_id="O4" value="99" lower_limit="37" upper_limit="321"/>
                    <measurement group_id="O5" value="37" lower_limit="37" upper_limit="42"/>
                    <measurement group_id="O6" value="37" lower_limit="37" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRhant+Add-back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" lower_limit="140" upper_limit="481"/>
                    <measurement group_id="O2" value="134" lower_limit="117" upper_limit="183"/>
                    <measurement group_id="O3" value="187" lower_limit="81" upper_limit="569"/>
                    <measurement group_id="O4" value="106" lower_limit="37" upper_limit="321"/>
                    <measurement group_id="O5" value="165" lower_limit="128" upper_limit="223"/>
                    <measurement group_id="O6" value="37" lower_limit="37" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Similar analyses as primary outcome</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Progesterone</title>
        <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum progesterone was measured for clinical characteristics and to determine changes in sex hormones.</description>
        <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
        <population>Data presented are from those women who had FMD with usable images</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Progesterone</title>
          <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. Serum progesterone was measured for clinical characteristics and to determine changes in sex hormones.</description>
          <population>Data presented are from those women who had FMD with usable images</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.7" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.0" upper_limit="3.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.6" upper_limit="1.9"/>
                    <measurement group_id="O4" value="1.3" lower_limit="1.0" upper_limit="1.9"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.6" upper_limit="1.3"/>
                    <measurement group_id="O6" value="0.9" lower_limit="0.6" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.4" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.7" upper_limit="3.7"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.6" upper_limit="1.9"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.6" upper_limit="2.5"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.3" upper_limit="1.3"/>
                    <measurement group_id="O6" value="0.6" lower_limit="0.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRhant+Add-back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.6" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.6" upper_limit="3.6"/>
                    <measurement group_id="O4" value="1.6" lower_limit="0.7" upper_limit="4.9"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.6" upper_limit="1.0"/>
                    <measurement group_id="O6" value="0.6" lower_limit="0.6" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>same analysis as primary outcome</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Antioxidant Status (TAS)</title>
        <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. TAS is an antioxidant and is a biomarker of oxidative stress.</description>
        <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
        <population>Data are presented from participants that completed the endothelial function testing and who had usable images.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Antioxidant Status (TAS)</title>
          <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol. TAS is an antioxidant and is a biomarker of oxidative stress.</description>
          <population>Data are presented from participants that completed the endothelial function testing and who had usable images.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.2"/>
                    <measurement group_id="O2" value="1.4" spread="0.2"/>
                    <measurement group_id="O3" value="1.3" spread="0.2"/>
                    <measurement group_id="O4" value="1.3" spread="0.1"/>
                    <measurement group_id="O5" value="1.3" spread="0.2"/>
                    <measurement group_id="O6" value="1.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.1"/>
                    <measurement group_id="O3" value="1.3" spread="0.2"/>
                    <measurement group_id="O4" value="1.3" spread="0.2"/>
                    <measurement group_id="O5" value="1.3" spread="0.1"/>
                    <measurement group_id="O6" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRhant+Add-back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                    <measurement group_id="O2" value="1.4" spread="0.1"/>
                    <measurement group_id="O3" value="1.3" spread="0.1"/>
                    <measurement group_id="O4" value="1.3" spread="0.1"/>
                    <measurement group_id="O5" value="1.3" spread="0.2"/>
                    <measurement group_id="O6" value="1.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Endothelin-1 (ET-1)</title>
        <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
        <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
        <population>Data are presented from women who completed endothelial function testing and whom had usable images</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelin-1 (ET-1)</title>
          <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
          <population>Data are presented from women who completed endothelial function testing and whom had usable images</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.5"/>
                    <measurement group_id="O2" value="5.2" spread="0.9"/>
                    <measurement group_id="O3" value="5.9" spread="1.3"/>
                    <measurement group_id="O4" value="6.2" spread="1.6"/>
                    <measurement group_id="O5" value="6.2" spread="1.4"/>
                    <measurement group_id="O6" value="6.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="1.7"/>
                    <measurement group_id="O2" value="5.5" spread="0.9"/>
                    <measurement group_id="O3" value="6.0" spread="1.8"/>
                    <measurement group_id="O4" value="5.9" spread="0.9"/>
                    <measurement group_id="O5" value="6.5" spread="2.1"/>
                    <measurement group_id="O6" value="6.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRhant+Add-back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.1"/>
                    <measurement group_id="O2" value="5.0" spread="0.7"/>
                    <measurement group_id="O3" value="5.9" spread="1.6"/>
                    <measurement group_id="O4" value="5.7" spread="1.9"/>
                    <measurement group_id="O5" value="6.0" spread="1.8"/>
                    <measurement group_id="O6" value="6.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Norepinephrine</title>
        <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
        <time_frame>Baseline, Day 4 GnRHant, Day 7 GnRHant+Add-back</time_frame>
        <population>Data are presented from women who completed endothelial function testing and whom had useable images.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre1</title>
            <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O2">
            <title>Pre2</title>
            <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O3">
            <title>Peri1</title>
            <description>Perimenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O4">
            <title>Peri2</title>
            <description>Perimenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O5">
            <title>Post1</title>
            <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
          <group group_id="O6">
            <title>Post2</title>
            <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Norepinephrine</title>
          <description>This other outcome measure was originally specified as &quot;Secondary&quot; in error and has been updated to &quot;Other, Pre-specified&quot; to be consistent with the protocol.</description>
          <population>Data are presented from women who completed endothelial function testing and whom had useable images.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" lower_limit="108" upper_limit="230"/>
                    <measurement group_id="O2" value="184" lower_limit="101" upper_limit="217"/>
                    <measurement group_id="O3" value="227" lower_limit="168" upper_limit="280"/>
                    <measurement group_id="O4" value="247" lower_limit="164" upper_limit="295"/>
                    <measurement group_id="O5" value="231" lower_limit="127" upper_limit="349"/>
                    <measurement group_id="O6" value="242" lower_limit="228" upper_limit="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRHant alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="116" upper_limit="164"/>
                    <measurement group_id="O2" value="156" lower_limit="103" upper_limit="252"/>
                    <measurement group_id="O3" value="235" lower_limit="183" upper_limit="282"/>
                    <measurement group_id="O4" value="233" lower_limit="159" upper_limit="341"/>
                    <measurement group_id="O5" value="280" lower_limit="156" upper_limit="362"/>
                    <measurement group_id="O6" value="217" lower_limit="180" upper_limit="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GnRhant+Add-back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" lower_limit="118" upper_limit="214"/>
                    <measurement group_id="O2" value="217" lower_limit="152" upper_limit="282"/>
                    <measurement group_id="O3" value="231" lower_limit="168" upper_limit="295"/>
                    <measurement group_id="O4" value="217" lower_limit="152" upper_limit="282"/>
                    <measurement group_id="O5" value="204" lower_limit="168" upper_limit="280"/>
                    <measurement group_id="O6" value="221" lower_limit="162" upper_limit="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants were asked at each vascular visit to complete a symptom questionnaire. These data were reviewed immediately by the PI and the study physician. Further, these data were summarized for the Safety Officer annually.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pre1</title>
          <description>Premenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="E2">
          <title>Pre2</title>
          <description>Premenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="E3">
          <title>Peri1</title>
          <description>Perimenopausal (early and late combined) - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="E4">
          <title>Peri2</title>
          <description>Perimenopausal (early and late combined) - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="E5">
          <title>Post1</title>
          <description>Postmenopausal - GnRHant plus estradiol&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal estradiol patch: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
        <group group_id="E6">
          <title>Post2</title>
          <description>Postmenopausal - GnRHant plus placebo&#xD;
GnRHant - Ganirelix acetate: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7&#xD;
Transdermal placebo patch: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular/neurology</sub_title>
                <description>Vasal vagal to nitrogylcerine</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Other urogenital</sub_title>
                <description>Vaginal discharge, dryness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Dermatology</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Patch irritation</sub_title>
                <description>Transdermal patch irritation, redness</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Budget cuts lead to: 1) endothelial cell protein expression outcome not analyzed and deleted; 2) small numbers of early and late perimenopausal groups, thus, it was collapsed into 1 peri group. Ultrasound image quality also lead to small numbers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kerrie Moreau. PI</name_or_title>
      <organization>University of Colorado Anschutz Medical Campus</organization>
      <phone>303-724-1914</phone>
      <email>kerrie.moreau@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

